100 years of Alzheimer's disease research: Are we any closer to a cure?

Aging Health

Volumn 3, Issue 3, 2007, Pages 279-282

  Lukiw, Walter J ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; CHELATING AGENT; CITALOPRAM; DOCOSAHEXAENOIC ACID; DONEPEZIL; FISH OIL; FLUOXETINE; GALANTAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PAROXETINE; PLANT MEDICINAL PRODUCT; RIVASTIGMINE; SERTRALINE; TRAZODONE;

AGE; ALZHEIMER DISEASE; AMNESIA; ANGIOGENESIS; BEHAVIOR DISORDER; CLINICAL FEATURE; CLINICAL PROTOCOL; CONFUSION; DEPRESSION; DISORIENTATION; DRUG ACTIVITY; DRUG EFFICACY; EDITORIAL; HUMAN; LIFE EXPECTANCY; MEDICAL RESEARCH; MENTAL DISEASE; MOOD DISORDER; PATHOGENESIS; PSYCHOSIS; RISK FACTOR;

EID: 34250814229     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/1745509X.3.3.279     Document Type: Editorial

References (34)

1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR: An English translation of Alzheimer's 1907 paper "Uber eine eigenartige Erkankung der Hirnrinde". Clin. Anat. 8, 429-431 (1995).
2. Mott RT, Hulette CM: Neuropathology of Alzheimer's disease. Neuroimaging Clin. North Am. 15, 755-765 (2005).
3. Hardy J: A hundred years of Alzheimer's disease research. Neuron 52, 3-13 (2006).
4. Iqbal K, Grundke-Iqbal I: Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. J. Alzheimer Dis. 9, 219-242 (2006).
5. Armstrong RA: Plaques and tangles and the pathogenesis of Alzheimer's disease. Folia Neurupathol. 44, 1-11 (2006).
6. Zlokovic BV: Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28, 202-208 (2005).
7. Humpel C, Marksteiner J: Cerebrovascular damage as a cause for Alzheimer's disease. Curr. Neurovasc. Res. 2, 341-347 (2005).
8. Lukiw WJ: Cholesterol and 24S-hydroxycholesterol trafficking in Alzheimer's disease. Expert Rev. Neurother. 6, 683-693 (2006).
9. Ferri CP, Prince M, Brayne C et al.: Alzheimer's disease international. Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117 (2005).
10. Zhu CW, Scarmeas N, Torgan R et al.: Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. Neurology 67, 998-1005 (2006).
11. Thal LJ: Prevention of Alzheimer disesse. Alzheimer Dis. Assoc. Disord. 20, S97-S99 (2006).
12. McGeer PL, McGeer EG: NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging 28, 639-647 (2007).
13. Vellas B, Andrieu S, Sampaio, C, Wilcock G: Disease-modifying trials in Alzheimer's disease: a European Task Force group. Lancet Neurol. 6, 56-62 (2007).
14. Schutte DL: Alzheimer disease and genetics: anticipating the questions. Am. J. Nurs. 106, 40-47 (2006).
15. Caselli RJ, Beach TG, Yaari R, Reiman EM: Alzheimer's disease a century later. J. Clin. Psychiatry 67, 1784-1800 (2006).
16. Estrada LD, Soto C: Disrupting β-amyloid aggregation for Alzheimer disease treatment. Curr. Top. Med. Chem. 7, 115-126 (2007).
17. Pogue AI, Lukiw WJ: Angiogenic signaling in Alzheimer's disease. Neuroreport 15, 1507-1510 (2004).
18. Vagnucci AH Jr, Li WW: Alzheimer's disease and angiogenesis. Lancet 361, 605-608 (2003).
19. Hull M, Berger M, Heneka M: Disease-modifying therapies in Alzheimer's disease: how far have we come? Drugs 66, 2075-2093 (2006).
20. Buckwalter MS, Coleman BS, Buttini M et al.: Increased T cell recruitment to the CNS after amyloid β 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-β1. J. Neurosci. 26, 11437-11441 (2006).
21. Monsonego A, Imitola J, Petrovic S et al.: Abeta-induced meningo-encephalitis is IFN-γ-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 103, 5048-5053 (2006).
22. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H: Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. BMJ 331, 321-327 (2005).
23. Courtney C, Farrell D, Gray R et al.: Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363, 2105-2115 (2004).
24. Lukiw WJ, Cui JG, Marcheselli VL et al.: A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Inverst. 115, 2774-2783 (2005).
25. Cole GM, Frautschy SA: Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model. Nutr. Health 18, 249-259 (2006).
26. Kruck TP, Cui JG, Percy ME, Lukiw WJ: Molecular shuttle chelation: the use of ascorbate, desferrioxamine and Feralex-G in combination to remove nuclear bound aluminum. Cell. Mol. Neurobiol. 24, 443-459 (2004).
27. Ren Y, Houghton P, Hider RC: Relevant activities of extracts and constituents of animals used in traditional Chinese medicine for central nervous system effects associated with Alzheimer's disease. J. Pharm. Pharmacol. 58, 989-996 (2006).
28. Wang R, Yan H, Tang XC: Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol. Sin. 27, 1-26 (2006).
29. Prasad KN, Cole WC, Prasad KC: Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. J. Am. Coll. Nutr. 21, 506-522 (2002).
30. Boedker M, Boetkjaer A, Bezan NG et al.: Budesonide epimer R, LAU-8080 and phenyl butyl nitrone synergistically repress cyclooxygenase-2 induction in [IL-1β+Aβ42]-stressed human neural cells. Neurosci. Lett. 380, 176-180 (2005).
31. Alegret M, Silvestre JS: Pleiotropic effects of statins and related pharmacological axperimental approaches. Methods Find. Exp. Clin. Pharmacol. 28, 627-656 (2006).
32. Rajanikant GK, Zemke D, Kassab M, Majid A: The therapeutic potential of statins in neurological disorders. Curr. Med. Chem. 14, 103-112 (2007).
33. Zhao Y, Cui JG, Lukiw WJ: Natural secretory products of human neural and microvessel endothelial cells: Implications in pathogenic "spreading" and Alzheimer's disease. Mol. Neurobiol. 34, 181-192 (2006).
34. Cui JG, Hill JM, Zhao Y, Lukiw WJ: Expression of inflammatory genes in the primary visual cortex of late-stage Alzheimer's disease. Neuroreport 18, 115-119 (2007).